Stocks · News reference

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Aug 11, 2026, 8:36 PMBenzinga Newsdesk

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SVRA

Source: benzinga
Observed: Aug 11, 2026, 8:36 PM
Checked: Aug 11, 2026, 8:37 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 8:08 PMBenzinga Newsdesk
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3
Read original at benzinga
SVRA
BenzingaAug 11, 2026, 9:01 PMBenzinga Newsdesk
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed
Read original at benzinga
SVRA
BenzingaJul 30, 2026, 12:12 PMBenzinga Newsdesk
Savara Announces European And Australian Patents Granted Covering MOLBREEVI Liquid Formulation, Securing Protection Through March 2041
Read original at benzinga
SVRA

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Connected markets

Related headlines

Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

Savara Announces European And Australian Patents Granted Covering MOLBREEVI Liquid Formulation, Securing Protection Through March 2041